Clinical Trial Update: Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 pharmacogenomics trial evaluating alectinib with SNPs in patients with non-small cell lung cancer; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alectinib (alectinib)

Snippet

Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Conditions: Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING